Campo DC | Valor | Idioma |
dc.contributor.author | Oliveira, Márcio Galvão | - |
dc.contributor.author | Passos, Luiz Carlos | - |
dc.contributor.author | Santos Júnior, Edval Gomes dos | - |
dc.contributor.author | Barbosa, Andréa Cristina Costa | - |
dc.contributor.author | Santos, Djanilson Barbosa | - |
dc.creator | Oliveira, Márcio Galvão | - |
dc.creator | Passos, Luiz Carlos | - |
dc.creator | Santos Júnior, Edval Gomes dos | - |
dc.creator | Barbosa, Andréa Cristina Costa | - |
dc.creator | Santos, Djanilson Barbosa | - |
dc.date.accessioned | 2015-04-30T13:19:07Z | - |
dc.date.available | 2015-04-30T13:19:07Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1984-8250 | - |
dc.identifier.uri | http://repositorio.ufba.br/ri/handle/ri/17510 | - |
dc.description | p.831-836 | pt_BR |
dc.description.abstract | The aim of this study was to use indicators to evaluate physician adherence to prescription guidelines for heart failure treatment in a university hospital. This was a prospective cohort study conducted in a university hospital. The information collected at the time of patient admission, including therapeutic indication, absolute contra indications and intolerance, was utilised for the formulation of a guideline adherence indicator (GAI). This indicator was calculated as follows: (the number of patients who used the medication/the number of eligible patients) x 100. The percentage of eligible patients was calculated using the following formula: (the number of eligible patients/the total number patients) x 100. The GAI was applied to a population of 53 patients. Inhibitors of angiotensin-converting enzyme/angiotensin receptor blocker (ACE-I/ARB) combination therapy were used in the greatest percentage of eligible patients (92.4%) and demonstrated the largest GAI value (73.5%). The percentages of patients who were eligible for beta-blockers, spironolactone and digitalis treatments were 81.1%, 52.8% and 60.4%, respectively. The GAI values for the use of beta-blockers, spironolactone and digitalis were 60.4%, 57.1% and 56.2%, respectively. For the studied patient population, the GAI was consistent with the proportion of patients who were eligible to receive digitalis and spironolactone. | pt_BR |
dc.language.iso | en | pt_BR |
dc.rights | Acesso Aberto | pt_BR |
dc.source | http://dx.doi.org/10.1590/S1984-82502013000400023 | pt_BR |
dc.subject | Heart failure/treatment | pt_BR |
dc.subject | Health care | pt_BR |
dc.subject | Clinical medicine/practice guidelines | pt_BR |
dc.subject | Medicines/use | pt_BR |
dc.subject | Medicines/prescriptions | pt_BR |
dc.title | Use of an indicator to evaluate physician adherence to prescription guidelines for the treatment of heart failure | pt_BR |
dc.title.alternative | Brazilian Journal of Pharmaceutical Sciences | pt_BR |
dc.type | Artigo de Periódico | pt_BR |
dc.identifier.number | v. 49, n. 4 | pt_BR |
Aparece nas coleções: | Artigo Publicado em Periódico (ICS)
|